Table 1.
Subject demographics and other relevant characteristics among Trulene® and Prolene® groups
| Subject characteristics | Trulene® (n = 46) | Prolene® (n = 43) | p value |
|---|---|---|---|
| Demographics | |||
| Gender, n (%): | 0.81 | ||
| Male | 41 (89.13) | 39 (90.70) | |
| Female | 5 (10.87) | 4 (9.30) | |
| Age (years), mean ± SD | 57.48 ± 11.90 | 63.75 ± 7.64 | 0.004* |
| Anthropometrics | |||
| Weight (kg), Mean ± SD | 69.98 ± 10.96 | 68.11 ± 10.18 | 0.34 |
| Height (cm), Mean ± SD | 164.84 ± 9.03 | 163.14 ± 7.71 | 0.41 |
| BMI (kg/m2), Mean ± SD | 25.83 ± 4.17 | 25.55 ± 3.24 | 0.72 |
| Vital signs | |||
| Pulse rate (beats per minute), Mean ± SD | 81.74 ± 10.86 | 83.37 ± 12.90 | 0.52 |
| Respiratory rate (respiration per minute), Mean ± SD | 19.00 ± 2.68 | 19.49 ± 2.25 | 0.47 |
| Systolic blood pressure (mmHg), Mean ± SD | 122.96 ± 15.87 | 129.98 ± 18.36 | 0.06 |
| Diastolic blood pressure (mmHg), Mean ± SD | 73.91 ± 91.15 | 74.70 ± 10.36 | 0.71 |
| Other characteristics | |||
| ASA classification, n (%): | 0.01* | ||
| ASA II | 1 (2.17) | 9 (20.93) | |
| ASA III | 45 (97.83) | 34 (79.07) | |
| NYHA grade, n (%): | 0.56 | ||
| NYHA I | 1 (2.17) | 0 | |
| NYHA II | 21 (45.65) | 18 (41.86) | |
| NYHA III | 24 (52.18) | 25 (58.14) | |
| Cardiac disease and reason for surgery, n (%): | 0.43 | ||
| Left main disease only | 0 | 1 (2.33) | |
| Left main disease in combination with a double vessel disease | 0 | 2 (4.65) | |
| Left main disease in combination with a multi vessel disease | 5 (10.86) | 3 (6.98) | |
| Double vessel disease only | 6 (13.05) | 4 (9.30) | |
| Multivessel disease | 35 (76.09) | 33 (76.74) | |
| Medical/surgical history | |||
| Endocrine, nutritional and metabolic diseases: | 0.81 | ||
| Diabetes mellitus | 28 (60.87) | 26 (60.47) | |
| Hypothyroidism | 6 (13.04) | 2 (4.65) | |
| Dyslipidemia | 1 (2.17) | 1 (2.33) | |
| Diseases of the circulatory system: | 0.14 | ||
| Hypertension | 31 (67.39) | 29 (67.44) | |
| IHD/CAD | 13 (28.26) | 13 (30.23) | |
| Myocardial Infarction | 3 (6.52) | 1 (2.33) | |
| Heart failure with midrange ejection fraction | 1 (2.17) | 0 | |
| Triple Vessel Disease | 1 (2.17) | 0 | |
| Cardiac Illness | 0 | 1 (2.33) | |
| Diseases of the musculoskeletal system and connective tissue: | 0.33 | ||
| Left femur fracture and surgery | 0 | 1 (2.33) | |
| Hip-joint replacement | 0 | 1 (2.33) | |
| Diseases of the digestive system: | 0.32 | ||
| OesophagoGastroDuodenoscopy and H. Pyroli infection | 1 (2.17) | 0 | |
| Diseases of the respiratory system: | 0.35 | ||
| Asthma | 1 (2.17) | 0 | |
| Tuberculosis | 0 | 1 (2.33) | |
| COVID-19 | 1 (2.17) | 3 (6.98) | |
| Diseases of the nervous system: | 0.60 | ||
| Cerebrovascular accident | 1 (2.17) | 1 (2.33) | |
| Parkinsonism | 1 (2.17) | 0 | |
| Diseases of the eye and adnexa: | 0.30 | ||
| S/P bilateral cataract surgery | 0 | 1 (2.33) | |
| Diseases of the genitourinary system: | 0.33 | ||
| Benign prostatic hyperplasia | 1 (2.17) | 0 | |
| Chronic kidney disease | 1 (2.17) | 0 | |
Bold numerals indicate P-values are </= 0.05
ASA American Society of Anaesthesiologists, IHD/CAD Ischemic Heart Disease/Coronary Artery Disease, NYHA New York Heart Association, S/P Status Post, SD standard deviation
*p < 0.05